---
title: Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis
nct_id: NCT03104322
overall_status: COMPLETED
phase: NA
sponsor: patientMpower Ltd.
study_type: INTERVENTIONAL
primary_condition: Idiopathic Pulmonary Fibrosis
countries: Ireland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03104322.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03104322"
ct_last_update_post_date: 2019-04-02
last_seen_at: "2026-05-12T06:23:39.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis

**Official Title:** A Randomised, Crossover Study of Self-monitoring of Symptoms and Spirometry Via the patientMpower Platform in Patients With Idiopathic Pulmonary Fibrosis

**NCT ID:** [NCT03104322](https://clinicaltrials.gov/study/NCT03104322)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 7
- **Lead Sponsor:** patientMpower Ltd.
- **Collaborators:** Health Service Executive, Ireland
- **Conditions:** Idiopathic Pulmonary Fibrosis
- **Start Date:** 2017-06-15
- **Completion Date:** 2018-03-09
- **CT.gov Last Update:** 2019-04-02

## Brief Summary

Pilot-scale, open-label, fixed-order, two-period crossover study in idiopathic pulmonary fibrosis (IPF) over 16 weeks. Patients will use an electronic health journal (patientMpower platform) to record treatment compliance, forced vital capacity (FVC; daily), impact of IPF on daily life (weekly) and other symptoms. Objectives are to characterise acceptability of patientMpower platform from patient \& healthcare professional perspective, impact of active engagement and self-monitoring using patientMpower platform on Patient Reported Outcome Measures (PROMs) in IPF, impact of patientMpower platform on medication compliance and correlation between patient-reported PROMs \& FVC and clinical outcomes.

## Eligibility

- **Minimum age:** 40 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* confirmed diagnosis of idiopathic pulmonary fibrosis (IPF).
* daily unrestricted access to smartphone or tablet device at home.
* demonstrated understanding of protocol and correct use of Spirobank Smart spirometer and patientMpower platform.
* able and willing to perform spirometry every day at home.
* willing to give written informed consent

Exclusion Criteria:

* significant confusion or any concomitant medical condition which would limit the ability of the patient to record symptoms or use a home spirometer on a regular basis.
* new prescription of antifibrotic therapy for IPF (e.g. pirfenidone, nintedanib) within 4 weeks before baseline visit.
* recent exacerbation of IPF or other clinically significant change in the patient's medical condition in 4 weeks before baseline visit
```

## Arms

- **Observation sequence** (OTHER) — Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks

## Interventions

- **patientMpower platform** (OTHER) — electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
- **usual care** (OTHER) — usual care

## Primary Outcomes

- **Acceptability of patientMpower Platform From Patient & Healthcare Professional Perspective** _(time frame: single measurement at 8 weeks)_ — Questionnaire-based assessment of response to questions: \[pMp = patientMpower platform\]

1. instructions for using pMp were clear
2. pMp helped me take the correct dose medicines
3. pMp helped me to take my medicines at the correct time
4. pMp helped me to reach my personal exercise goal
5. pMp helped me to walk further
6. pMp gave me a greater sense of control
7. useful to be able to record the impact of lung fibrosis on QoL
8. pMp encouraged me to look at the informational videos
9. preference for using pMp
10. difficulty in using pMp
11. effect of pMp on impact on daily life
12. tiring/irritating to use pMp
13. want to continue using pMp after study
14. would recommend pMp to others Possible responses Q1-8, Q12: strongly agree/agree/disagree/strongly disagree Q9: yes/no preference/no Q10: very easy/easy/difficult/very difficult Q11: positive/negative/open text Q13,14: yes/no

## Secondary Outcomes

- **Medication Compliance (Days Medication Taken/Observation Period Days)** _(time frame: 8 weeks)_
- **Idiopathic Pulmonary Fibrosis Patient Reported Outcome Measure (IPF-PROM)** _(time frame: Baseline visit)_
- **Patient-reported Exercise Performance** _(time frame: 8 weeks)_
- **Patient-reported Forced Vital Capacity (FVC)** _(time frame: 8 weeks)_

## Locations (1)

- Dept. of Respiratory Medicine, Galway, Ireland

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.dept. of respiratory medicine|galway||ireland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03104322.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03104322*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*